Caplyta Study Strengthens JNJ's Clinical Story Amid Valuation Pressures

Johnson & Johnson's (JNJ) shares slipped by about 0.1% to $266.965 after new late-stage data revealed improved sexual functioning among depression patients taking Caplyta, a medication already approved for schizophrenia and bipolar depression.

The study involved 480 participants, with over 80% reporting sexual dysfunction prior to treatment. Those receiving 42 milligrams of Caplyta alongside their existing antidepressants showed statistically significant improvements in measures including desire, arousal, orgasm, and pleasure compared to placebo.

Caplyta's differentiation may extend beyond symptom control, expanding the strategic value of J&J's $14.6 billion acquisition of Intra-Cellular Therapies, which equals roughly 57.7% of J&J's latest $25.3 billion in quarterly sales.

The new data strengthen Caplyta's clinical story, but investors now need better patient retention and stronger sales growth to justify the acquisition price and current valuation, as J&J shares trade 38.04% above their estimated value.